TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in anti-mullerian hormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in follicle stimulating hormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in luteinizing hormone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Balance (Functional Reach)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Economy of movement (Oxygen consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capacity (Continuous Scale Physical Functional Performance Test (Cs-PFP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Roland-Morris Low Back Pain and Disability Questionnaire (RMDQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Fear Avoidance Beliefs Questionnaire (FABQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Data collected from individual semi-structured interviews
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Continuous Performance Test Raw Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Stability gain or loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Limb support gain or loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Real life falls
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PRISM Chagas Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRISM Chagas Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ESA Chagas Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ESA Chagas Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean overall physical activity level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Urethral Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Five Year Event-free Survival (EFS)
Endpoint domain: Mortality/survival
Primary endpoint: Blood cell counts (neutropenia, thrombocytopenia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum chemistries (liver function tests)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum chemistries (creatinine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum concentration of C-terminal telopeptide (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: N-terminal propeptide of type 1 procollagen (P1NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline radiographic evidence of alveolar crestal bone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall production cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cerebral regional oxygen saturation (rScO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Authorization for preparation of chemotherapy based on clinical information
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Authorization for preparation of chemotherapy based on patient reported outcome
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: maximum tolerated dose (MTD) of SAR125844
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preliminary anti-tumoral effect of SAR125844
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with satisfactory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Level of satisfaction with hospitalization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hemoglobin A1c Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Mood Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline homeostasis model assessment-estimated insulin resistance (HOMA-IR) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Neurocognitive performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence of Grade II-IV Acute Graft vs. Host Disease (GVHD)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of successful treatment episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in total wound size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of adverse event occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Localization of peripheral pulmonary lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Onset time of sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prefrontal functional connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rate of hospitalization for patients with CHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success of Pneumatic Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with controlled seated diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with at Least One Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Progression Free Survival
Endpoint domain: Physiological/clinical
Primary endpoint: Muscular activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: change in cerebral tissue oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Benefit Response
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total duration of standby periods during NREM and REM phases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gastric emptying kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in HAM-D17 Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wang Qi Chinese Medicine Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tmax of Venetoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of EE/Levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of EE/Levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of Venetoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of EE/Levonorgestrel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Fugl-Meyer Assessment scale (upper extremity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined categorized endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flurbiprofen Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ketoprofen Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolbutamide Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geriatric Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Penn State Worry Questionnaire (PSWQ-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Generalized Anxiety Disorder-7
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum uric acid elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients achieving 20% improvement (ACR20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Penetrating injury rate
Endpoint domain: Adverse events/effects
Primary endpoint: Polysomnography parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Effectivity of virtual chromoendoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lamotrigine AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from TLR (Target Lesion Revascularization)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Open (functioning and not stenosed) vascular reconstruction (Primary Patency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall Decrease in Wound Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: MADRS-S score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean reflective nasal congestion/stuffiness symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of ICG imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Skin Foldability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Patients Detected With Ventricular Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Detected With Pericardial Effusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Detected With Valvular Disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Detected With Septal Disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Detected With Coronary Anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Responders at the End of the Core Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Responders at the End of the Extension Treatment Period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of visual acuity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Self-assessed function (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Non-infection Within One Year
Endpoint domain: Adverse events/effects
Primary endpoint: success rate of analgesic methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days-alive-out-of-hospital
Endpoint domain: Mortality/survival
Primary endpoint: time to perform block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of attempts to perform block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficacy of the block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total visit time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intraoperative nausea and vomiting (IONV)
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody-mediated rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sensitivity and specificity of MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset of other neoplasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of days with no heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality of life Questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Leg biomechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg hemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUSCAN (Australian Canadian Osteoarthritis Hand Index)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Estimated Blood Loss (EBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Standardized Baseline-Adjusted FEV1 AUEC0-12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Morning Trough FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in auditory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete renal function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Partial renal function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: All cause-death
Endpoint domain: Mortality/survival
Primary endpoint: paucity of serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Failed flight/dive simulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antral follicular count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: AntiMullerian hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Incidence of chronic post surgical pain (CPSP) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occupancy of D2/3 receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spasticity of Gastrocnemius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Unrecognised Heart Failure With Preserved Ejection Fraction (HFpEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease from Rest of Oxygen Pressure (DROP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Average Daily Micturitions at Week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants Who Had Study Medication Withdrawn Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Change in memory function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intervention Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recruitment Yields
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Program Retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Average Daily Caloric Intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative intraoperative administration of norepinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax of probe substrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast of probe substrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf of probe substrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: BOLD signal response to food cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic intracranial haemorrhages
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of non-symptomatic intracranial haemorrhages
Endpoint domain: Mortality/survival
Primary endpoint: Change in Proteinuria - Uprotein/Creatinine Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of Vaso-occlusive Crises (VOCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Blood Epinephrine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Blood Norepinephrine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of total retinal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Patients Achieving a Target of Fasting LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood levels of leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood levels of adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood levels of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood levels of TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood levels of C-Reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean IOP at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dry skin severity
Endpoint domain: Adverse events/effects
Primary endpoint: Total calories consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart Failure Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Glycated Haemoglobin (HbA1c) (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients With Treatment Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative treatment failure at 52 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Treatment-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: persistence with Actonel 5 mg daily therapy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of patients with Ultrasound call signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative Dix-Hallpike maneuver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Salivary Alpha Amylase concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to next UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in the Intensity of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concomitant orders for warfarin and tmp/smx
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SNOT-20 Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Total Oral Mucosal Area Covered by Warts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Changes in trunk adipose mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Completing Secondary School
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Participants Married
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAT receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response of renal plasma flow to L-NMMA infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvement on the Hamilton Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neurotoxicity as Measured by a Scored Neurologic Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serial Reaction Time Task (SRTT) Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accessibility of endoscopic approaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of Glycosylated Haemoglobin A1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes